Peringatan Keamanan

Central nervous system depression

Dexchlorpheniramine maleate

DB09555

small molecule approved

Deskripsi

Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

Struktur Molekul 2D

Berat 390.86
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 20-30 h
Volume Distribusi 321L
Klirens (Clearance) 9.8L/h

Absorpsi

Oral bioavailability in rats 40.5%

Metabolisme

Hepatic metabolism. Major metabolism by CYP 2D6 and minor metabolism by 3A4, 2C11 and 2B1.

Rute Eliminasi

Renal excretion

Interaksi Makanan

1 Data
  • 1. Avoid alcohol. Alcohol may have additive CNS depressant effects with dexchlorpheniramine maleate.

Interaksi Obat

783 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Dexchlorpheniramine maleate.
Benzylpenicilloyl polylysine Dexchlorpheniramine maleate may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexchlorpheniramine maleate.
Mirabegron The serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Mirabegron.
Amphetamine Amphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Phentermine Phentermine may decrease the sedative activities of Dexchlorpheniramine maleate.
Benzphetamine Benzphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Diethylpropion Diethylpropion may decrease the sedative activities of Dexchlorpheniramine maleate.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Mephentermine Mephentermine may decrease the sedative activities of Dexchlorpheniramine maleate.
MMDA MMDA may decrease the sedative activities of Dexchlorpheniramine maleate.
Midomafetamine Midomafetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Dexchlorpheniramine maleate.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Metamfetamine Metamfetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Dexchlorpheniramine maleate.
Ritobegron Ritobegron may decrease the sedative activities of Dexchlorpheniramine maleate.
Mephedrone Mephedrone may decrease the sedative activities of Dexchlorpheniramine maleate.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Gepefrine Gepefrine may decrease the sedative activities of Dexchlorpheniramine maleate.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Dexchlorpheniramine maleate.
Citalopram The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Valproic acid.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Grepafloxacin.
Toremifene The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Toremifene.
Imatinib The serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Imatinib.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Cocaine.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Arsenic trioxide.
Domperidone The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Sparfloxacin.
Bepridil The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Tetrabenazine.
Iloperidone The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Artemether.
Vemurafenib The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Vemurafenib.
Glasdegib The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Terodiline.
Eliglustat The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Eliglustat.
Quinidine The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Quinidine.
Dofetilide The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Dofetilide.
Cisapride The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Cisapride.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine maleate.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine maleate.
Erythromycin The serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Dexchlorpheniramine maleate.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine maleate.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Dexchlorpheniramine maleate.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Dexchlorpheniramine maleate.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Dexchlorpheniramine maleate.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Dexchlorpheniramine maleate.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Dexchlorpheniramine maleate.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Dexchlorpheniramine maleate.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Dexchlorpheniramine maleate.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dexchlorpheniramine maleate.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dexchlorpheniramine maleate.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Dexchlorpheniramine maleate.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dexchlorpheniramine maleate.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Dexchlorpheniramine maleate.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dexchlorpheniramine maleate.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Dexchlorpheniramine maleate.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Dexchlorpheniramine maleate.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Dexchlorpheniramine maleate.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dexchlorpheniramine maleate.
Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Dexchlorpheniramine maleate.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Dexchlorpheniramine maleate.
Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Dexchlorpheniramine maleate.
Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Dexchlorpheniramine maleate.
Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Dexchlorpheniramine maleate.
Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Dexchlorpheniramine maleate.
Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Dexchlorpheniramine maleate.
Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Dexchlorpheniramine maleate.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Dexchlorpheniramine maleate.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Dexchlorpheniramine maleate.
Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dexchlorpheniramine maleate.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Dexchlorpheniramine maleate.
Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Dexchlorpheniramine maleate.
Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dexchlorpheniramine maleate.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Dexchlorpheniramine maleate.
Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Dexchlorpheniramine maleate.
Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Dexchlorpheniramine maleate.

Target Protein

Histamine H1 receptor HRH1

Referensi & Sumber

Synthesis reference: LI Pengfei LIU Lihong MA Ping WANG LingCHI Xiaohua LIANG Dongmei GAO Wenjing WANG Yanfeng(Department of Pharmacy,the Second Artillery General Hospital,PLA,100088,Beijing,China);PHARMACOKINETICS OF PARACETAMOL AND DEXCHLORPHENIRAMINE MALEATE ORAL SOLUTION IN HEALTHY VOLUNTEERSJ;Journal of Beijing Normal University(Natural Science);2008-03 Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-887.
Artikel (PubMed)
  • PMID: 20680237
    Angier E, Willington J, Scadding G, Holmes S, Walker S: Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline. Prim Care Respir J. 2010 Sep;19(3):217-22. doi: 10.4104/pcrj.2010.00044.
  • PMID: 10897096
    Bui TH, Fernandez C, Vu K, Nguyen KH, Thuillier A, Farinotti R, Arnaud P, Gimenez F: Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. Chirality. 2000 Aug;12(8):599-605.
  • PMID: 7106172
    Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL: Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur J Clin Pharmacol. 1982;22(4):359-65.
  • PMID: 10368923
    Hiep BT, Gimenez F, Khanh VU, Hung NK, Thuillier A, Farinotti R, Fernandez C: Binding of chlorpheniramine enantiomers to human plasma proteins. Chirality. 1999;11(5-6):501-4.
  • PMID: 9231341
    Nomura A, Sakurai E, Hikichi N: Stereoselective N-demethylation of chlorpheniramine by rat-liver microsomes and the involvement of cytochrome P450 isozymes. J Pharm Pharmacol. 1997 Mar;49(3):257-62.

Contoh Produk & Brand

Produk: 28 • International brands: 0
Produk
  • Abanatuss Ped
    Solution • - • Oral • US • OTC
  • Abanatuss Ped Drops
    Solution • - • Oral • US • OTC
  • Abatuss Dmx
    Liquid • - • Oral • US • OTC
  • Chlophedianol Hydrochloride, Dexchlorpheniramine Maleate, and Pseudoephedrine Hydrochloride
    Liquid • - • Oral • US • OTC
  • Corzall PE
    Liquid • - • Oral • US
  • DELTUSS DMX Cough Suppressant Nasal Decongestant Antihistamine GRAPE Flavor
    Liquid • - • Oral • US • OTC
  • DELTUSS DP Nasal Decongestant Antihistamine CHERRY Flavor
    Liquid • - • Oral • US • OTC
  • Dexchlorpheniramine Maleate
    Solution • 2 mg/5mL • Oral • US • Generic • Approved
Menampilkan 8 dari 28 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul